XML 91 R29.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Collaboration Agreements (Tables)
 12 Months Ended
Dec. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Summary of Collaboration Revenue
Revenue disaggregated by collaboration agreement and performance obligation is as follows (in thousands):
Year Ended December 31,
20192018
Takeda Collaboration Agreement(1)
$5,926  $5,677  
Sanofi Collaboration Agreement:
CNS Program License—  73,932  
Peripheral Program License10,000  47,148  
Alzheimer's Disease Services(1)
358  60  
Retained Activities10,394  2,343  
Total Sanofi Collaboration Revenue20,752  123,483  
Total Collaboration Revenue$26,678  $129,160  
_________________________________________________
(1)Amounts for the year ended December 31, 2019 represent revenue recognized that was included in the contract liability balance at the beginning of the year. There was no deferred revenue at the beginning of the year ended December 31, 2018. There was no collaboration revenue in the year ended December 31, 2017.